
What smart money is saying about ADMA Biologics
1 fund in our archive has pitched ADMA Biologics, most recently Renaissance IM Small Cap Growth in June 2025.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Get an email when a fund buys, sells or pitches it
Position history
Between Q2 2025 and Q2 2026, 2 fund letters reported a position in ADMA Biologics, with 1 buy (opened or added) and 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 1 | 0 |
| Q3 2025 | 1 | 1 | 0 | 0 |
| Q2 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions · 2 moves
- June 2026
“Health Care 20.1% -4.2% BrightSpring Health Services (ADMA Biologics, Catalyst Pharmaceuticals, GeneDx)”
ADMA Biologics - September 2025
“o two in health care: Mirum Pharmaceuticals, ADMA Biologics”
ADMA Biologics
Fund coverage · 1 thesis
- Renaissance IM Small Cap GrowthJune 2025
ADMA Biologics is a commercial-stage biopharma company focused on plasma-based biologics for immune deficiencies and infectious disease prevention, with strong growth prospects and a target of $1 billion in revenue by 2030.
Read the full thesis
Read every full thesis on ADMA Biologics
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→